Product: SPEAR UltraDetect a-syn

Enhance Neurodegenerative Detection and Monitoring with BD-pTau 217 and α-Syn

BD-pTau 217 and Alpha-Synuclein Biomarker Detection On-Demand Webinar Watch this on-demand webinar to learn how BD-pTau 217 and alpha-synuclein biomarker detection can support neurodegenerative disease research, including Alzheimer’s disease, Parkinson’s disease, and related synucleinopathies. Reliable measurement of blood-based neurodegenerative biomarkers remains a significant challenge, particularly for low-abundance targets such as brain-derived pTau 217, total alpha-synuclein, and pS129-alpha-synuclein. In […]

Read More

Blood-Based α-Synuclein and pS129-α-Synuclein Biomarkers for Parkinson’s Disease Research

Alpha-synuclein blood biomarkers are an important area of investigation in Parkinson’s disease and synucleinopathy research. For teams studying disease mechanisms, evaluating therapeutic strategies, or building better tools to monitor biological change, one question remains central: how can disease-relevant α-synuclein biology be measured sensitively, reliably, and at scale? Alpha-synuclein (α-synuclein) has long been central to Parkinson’s disease […]

Read More

Advancing Parkinson’s Disease and Synucleinopathy Research

Ultrasensitive α-Synuclein and pS129-α-Synuclein Assays for Biomarker Research α-Synuclein aggregation and misfolding are central pathological features of synucleinopathies, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). But detecting disease-relevant α-synuclein species in biofluids remains challenging due to low endogenous abundance, complex sample matrices, and the need to measure subtle […]

Read More